Treatment efficacy in a metastatic small intestinal neuroendocrine tumour grade 2 cohort
Endocrine-Related Cancer · 01.03.2023 · 30 (3)
DOI: 10.1530/erc-22-0316 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine-Related Cancer, erschienen am 01.03.2023. Verfasst von Dimitrios Papantoniou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Sciences, Endocrine Oncology, Uppsala University, Uppsala, Sweden. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Octreotide. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Small intestinal neuroendocrine tumours (Si-NET) are often studied as a uniform group. Proliferation index Ki-67 influences prognosis and determines tumour grade. We hypothesized that Si-NET grade 2 (G2) tumours, which have a higher Ki-67 than G1 tumours, might benefit less from established treatments for metastatic disease. We conducted a retrospective cohort study of 212 patients with metastatic Si-NET G2 treated in two Swedish hospitals during 20 years (2000–2019). Median cancer-specific survival on first-line somatostatin analogues (SSA) was 77 months. Median progression-free survival (PFS) was 12.4 months when SSA was given as monotherapy and 19 months for all patients receiving first-line SSA. PFS after SSA dose escalation was 6 months in patients with radiological progression. Treatment efficacies of SSA and peptide receptor radionuclide treatment (PRRT) were studied separately in patients with Ki-67 of 3–5%, 5–10% and 10–20%. For SSA, PFS was significantly shorter at higher Ki-67 levels (31, 18 and 10 months, respectively), while there was only a minor difference in PFS for PRRT (29, 25 and 25 months). Median PFS for sequential treatment with interferon-alpha (IFNα), everolimus and chemotherapy was 6, 5 and 9 months. IFNα seemed to be effective in tumours with low somatostatin–receptor expression. In conclusion, established treatments appeared effective in Si-NET G2, despite their higher proliferation index compared to G1 tumours. However, efficacy of SSA but not PRRT was reduced at higher Ki-67 levels. SSA dose escalation provided limited disease stabilization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Sciences, Endocrine Oncology, Uppsala University, Uppsala, Sweden.
- Department of Oncology, Ryhov County Hospital, Jönköping, Sweden.
- Oslo University Hospital, Rikshospitalet, Deptartment of Organ Transplant, Oslo, Norway.
- Haukeland Hospital, Deptartment of Oncology, Bergen, Norway.
- University of Bergen, Deptartment of Clinical Medicine, Bergen, Norway.
- Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
ORCID-Profile: Dimitrios Papantoniou
Zitieren
APA
Papantoniou, D., Grönberg, M., Thiis-Evensen, E., Sorbye, H., Landerholm, K., Welin, S., & Tiensuu Janson, E. (2023). Treatment efficacy in a metastatic small intestinal neuroendocrine tumour grade 2 cohort. Endocrine-Related Cancer, 30(3). https://doi.org/10.1530/erc-22-0316
Vancouver
Papantoniou D, Grönberg M, Thiis-Evensen E, Sorbye H, Landerholm K, Welin S, et al. Treatment efficacy in a metastatic small intestinal neuroendocrine tumour grade 2 cohort. Endocrine-Related Cancer. 2023;30(3). doi:10.1530/erc-22-0316
BibTeX
@article{Papantoniou2023,
author = {Papantoniou, Dimitrios and Grönberg, Malin and Thiis-Evensen, Espen and Sorbye, Halfdan and Landerholm, Kalle and Welin, Staffan and Tiensuu Janson, Eva},
title = {Treatment efficacy in a metastatic small intestinal neuroendocrine tumour grade 2 cohort},
journal = {Endocrine-Related Cancer},
year = {2023},
volume = {30},
number = {3},
doi = {10.1530/erc-22-0316}
}
EUVIMED